Ayse Tuba Kendi

Oct 4, 2024 | jnm.snmjournals.org | Jérémie Calais |Michael Morris |Ayse Tuba Kendi |Arash Rezazadeh Kalebasty

BEST PRACTICES FOR AE MANAGEMENTThe safety of [177Lu]Lu-PSMA-617 in patients with mCRPC has been established in the phase III VISION study (3,7) and the phase II studies TheraP and RESIST-PC (8,9). In the VISION study, the most commonly reported AEs with [177Lu]Lu-PSMA-617 treatment were fatigue, dry mouth, nausea, and anemia (Supplemental Table 1; supplemental materials are available at http://jnm.snmjournals.org) (3), generally consistent with reports from TheraP (8) and RESIST-PC (9).